BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...